Atherogenic Lipid Profile in Behçet's Disease: Evidence of Alteration of HDL Subclasses

Archives of Medical Research

Volumn 42, Issue 3, 2011, Pages 211-218

  Messedi, Meriam ^a   Jamoussi, Kamel ^a   Frigui, Makram ^b   Laporte, François ^c   Turki, Mouna ^a   Chaabouni, Khansa ^a   Mnif, Emna ^a   Jaloulli, Moez ^b   Kaddour, Neila ^b   Bahloul, Zouhir ^b   Ayedi, Fatma ^a  

^a UNIVERSITY OF SFAX   (Tunisia)

^b HEDI CHAKER HOSPITAL   (Tunisia)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Atherogenic risk; Beh et disease; HDL subclasses; Lipid profile; Lipoproteins

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CHOLESTEROL; COLCHICINE; CORTICOSTEROID; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BEHCET DISEASE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; EYE DISEASE; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; NEUROLOGIC DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BLOOD LEVEL; TANDEM MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY; VASCULAR DISEASE;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; BEHCET SYNDROME; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; MIDDLE AGED; PARTICLE SIZE; STATISTICS, NONPARAMETRIC; TRIGLYCERIDES; YOUNG ADULT;

EID: 79959695268     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.05.001     Document Type: Article

References (54)

1. Behçet H. Uber rezidivierende aphthouse durch ein virus verursachte Geschwuere am Mund, am Auge und an den Genitalien. Dermatol Monatsschr Wochenschr 1937, 105:1152-1157.
2. Sakane T., Takeno M., Suzuki N., et al. Behçet's disease. N Engl J Med 1999, 341:1284-1291.
3. Kural-Seyahi E., Fresko I., Seyahi N., et al. The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003, 82:60-76.
4. Oztürk M.A., Oktar S.O., Unverdi S., et al. Morphologic evidence of subclinical atherosclerosis obtained by carotid ultrasonography in patients with Behcet's disease. Rheumatol Int 2006, 26:867-872.
5. Lahita R.G., Rivkin E., Cavanagh I., et al. Low levels of total cholesterol, high-density lipoprotein and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993, 36:1566-1574.
6. Kumon Y., Suehiro T., Ikeda Y., et al. Influence of serum amyloid A protein on high-density lipoprotein in chronic inflammatory disease. Clin Biochem 1993, 26:505-511.
7. Tokay S., Direskeneli H., Yurdakul S., et al. Anticardiolipin antibodies in Behçet's disease: a reassessment. Rheumatology (Oxford) 2001, 40:192-195.
8. Orem A., Deĝer O., Memiş O., et al. Lp(a) levels as a predictor of thrombogenic events in patients with Behçet's disease. Ann Rheum Dis 1995, 54:726-729.
9. Musabak U., Baylan O., Cetin T., et al. Lipid profile and anticardiolipin antibodies in Behcet's disease. Arch Med Res 2005, 36:387-392.
10. Anon International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990, 335:1078-1080.
11. Friedewald W.T., Levy R.I., Frederickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clin Chem 1972, 18:499-502.
12. Warnick G.R., McNamara J.R., Boggess C.N., et al. Polyacrylamide gradient gel electrophoresis of lipoprotein subclasses. Clin Lab Med 2006, 26:803-846.
13. Lee Y.J., Kang S.W., Yang J.I., et al. Coagulation parameters and plasma total homocysteine levels in Behcet's disease. Thromb Res 2002, 106:19-24.
14. Orem A., Yandi Y.E., Vanizor B., et al. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxydant enzyme activities, and endothelial dysfunction in patients with Behçet's disease. Clin Biochem 2002, 35:217-224.
15. Gullu H., Caliskan M., Erdogan D., et al. Impaired coronary microvascular functions in patients with Behçet disease. J Am Coll Cardiol 2006, 48:586-587.
16. Ozkan Y., Yardim-Akaydin S., Sepici A., et al. Assessment of homocysteine, neopterin and nitric oxide levels in Behçet's disease. Clin Chem Lab Med 2007, 45:73-77.
17. Pamuk G.E., Pamuk O.N., Orüm H., et al. Might platelet-leucocyte complexes be playing a role in major vascular involvement of Behçet's disease? A comparative study. Blood Coagul Fibrinolysis 2010, 21:113-117.
18. Seyahi E., Ugurlu S., Cumali R., et al. Atherosclerosis in Behçet's Syndrome. Semin Arthritis Rheum 2008, 38:1-12.
19. Gordon T., Castelli W.P., Hjortland M.C., et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:7-14.
20. Svenungsson E., Jensen-Urstad K., Heimbürger M., et al. Risk factor for cardiovascular disease in systemic lupus erythematosus. Circulation 2001, 104:1887-1893.
21. Manger K., Kusus M., Forster C., et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003, 62:846-850.
22. Pahor A., Hojs R., Gorenjak M., etal Accelerated atherosclerosis in pre-menopausal female patients with rheumatoid arthritis. Rheumatol Int 2006, 27:119-123.
23. Roman M.J., Shanker B.A., Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406.
24. Asanuma Y., Oeser A., Shintani A.K., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407-2415.
25. Otvos J.D., Jeyarajah E.J., Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 2002, 905(suppl1):22-29.
26. Rosenson R.S., Otvos J.D., Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 2002, 90:89-94.
27. Stampfer M.J., Sacks F.M., Salvini S., et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991, 325:373-381.
28. Gaziano J.M., Hennekens C.H., O'Donnell C.J., et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997, 96:2520-2525.
29. Lagogianni I., Papapanagiotou A., Piperi C., et al. Evidence of reduced plasma HDL subfractions in patients with cutaneous discoid lupus erythematosus. Clin Biochem 2005, 38:286-290.
30. Johansson J., Carlson L.A., Landou C., et al High density lipoprotein concentration and development of ischaemic heart disease. Arterioscler Thromb 1991, 11:174-182.
31. Lamarche B., Moorjani S., Cantin B., et al. Associations of HDL2 and HDL3 subfractions and development of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997, 17:1098-1105.
32. Tato F., Vega G.L., Tall A.R., et al. Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1995, 15:112-120.
33. Leiba M., Seligsohn U., Sidi Y., et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease. Ann Rheum Dis 2004, 63:1445-1449.
34. Orem A., Deger O., Memis O., et al. Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behcet's disease. Ann Rheum Dis 1995, 54:726-729.
35. Ricart M.J., Vaya A., Santaolaria M., et al. Dyslipidaemia in Behçet's disease as a thrombotic risk factor. Ann Rheum Dis 2006, 65:1248-1249.
36. Watanabe H., Miyashita Y., Murano T., et al. Preheparin serum lipoprotein lipase mass concentration: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis 1999, 145:45-50.
37. Fried L.F., Katz R., Cushman M., et al. Changes in cardiovascular risk factor with progression of kidney disease. Am J Nephrol 2009, 29:334-341.
38. Dalghous A.M., Freysdottir J., Fortune F. Expression of cytokines, chemokines and chemokines receptors in oral ulcers of patients with Behcet's disease (BD) and current aphthous stomatitis is Th1-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol 2006, 35:472-475.
39. Hamzaoui K., Hamzaoui A., Guemira F., et al. Cytokine profile in Behçet's disease patients, relationship with disease activity. Scand J Rheumatol 2002, 31:205-210.
40. Kötter I., Koch S., Vonthein R., et al. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol 2005, 23:20-26.
41. Adam B., Calikoglu E. Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease. J Eur Acad Dermatol Venereol 2004, 18:318-320.
42. Akar A., Arca E., Serdar M.A., et al. Correlation between erythrocyte antioxidant activity, lipid peroxidation, and disease activity in patients with Behçet's disease. J Eur Acad Dermatol Venereol 2003, 17:482-483.
43. Taysi S., Kocer I., Memisogullari R., etal Serum oxidant/antioxidant status in patients with Behçet's disease. Ann Clin Lab Sci 2002, 32:377-382.
44. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
45. Masucci-Magoulas L., Moulin P., Jiang X.C., et al. Decreased cholesterol ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein after lipopolysaccharide administration in human CETP transgenic mice. J Clin Invest 1995, 95:1587-1594.
46. Kobayashi J., Tateishi S., Maruyama T., et al. Marked reduction in serum high-density lipoprotein cholesterol concentrations in a woman with acute inflammation due to diabetic gangrene. Clin Chem Acta 2003, 335:33-38.
47. Alvim R.O., Freitas S.R., Ferreira N.E., et al. APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population. Lipids Health Dis 2010, 9:128.
48. Tursen U., Eskandari G., Kaya T.I., et al. Apolipoprotein E polymorphism and lipoprotein compositions in patients with Behçet's disease. Int J Dermatol 2004, 43:900-903.
49. Khovidhunkit W., Kim M.S., Memon R.A., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004, 45:1169-1196.
50. Kinosian B., Glick H., Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994, 121:641-647.
51. Van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 2002, 46:862-873.
52. Rizzo M., Spinas G.A., Cesur M., et al. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. Atherosclerosis 2009, 207:502-506.
53. Fernandez M.L., Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. J Am Coll Nut 2008, 27:1-5.
54. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection.